Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells

BACKGROUND: Lapatinib is a commonly used drug that interrupts signaling from the epidermal growth factor receptors, EGFR and HER2/neu. Long-term exposure to lapatinib during therapy eliminates cells that are sensitive to the drug; however, at the same time it increases probability of lapatinib-resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaczyńska, Angelika, Herman-Antosiewicz, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318491/
https://www.ncbi.nlm.nih.gov/pubmed/27154770
http://dx.doi.org/10.1007/s12282-016-0700-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318491/
https://www.ncbi.nlm.nih.gov/pubmed/27154770
http://dx.doi.org/10.1007/s12282-016-0700-9

Ejemplares similares